OTCPK:GNGB.Y

Stock Analysis Report

Executive Summary

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions.

Snowflake

Fundamentals

Mediocre balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Getinge's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.6%

GNGB.Y

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

17.6%

GNGB.Y

9.7%

US Medical Equipment

0.7%

US Market

GNGB.Y outperformed the Medical Equipment industry which returned 9.9% over the past year.

GNGB.Y outperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

GNGB.YIndustryMarket
7 Day3.6%1.2%-0.6%
30 Day5.0%3.5%4.9%
90 Day-7.4%3.2%1.7%
1 Year18.2%17.6%10.6%9.7%3.0%0.7%
3 Year-8.0%-25.8%70.6%65.4%44.8%35.4%
5 Year-26.1%-41.6%139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Getinge's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Getinge undervalued based on future cash flows and its price relative to the stock market?

30%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Getinge's share price is below the future cash flow value, and at a moderate discount (> 20%).

Getinge's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Getinge is loss making, we can't compare its value to the US Medical Equipment industry average.

Getinge is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Getinge, we can't assess if its growth is good value.


Price Based on Value of Assets

Getinge is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Getinge expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

25.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Getinge's revenue is expected to grow by 3.8% yearly, however this is not considered high growth (20% yearly).

Getinge's earnings are expected to grow significantly at over 20% yearly.

Getinge's revenue growth is positive but not above the United States of America market average.

Getinge's earnings growth is expected to exceed the United States of America market average.

Getinge's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Getinge is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Getinge performed over the past 5 years?

-45.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Getinge does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Getinge's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Getinge's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Getinge has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Getinge has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Getinge improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Getinge's financial position?


Financial Position Analysis

Getinge is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Getinge's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Getinge's level of debt (53.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (117.2% vs 53.5% today).

Debt is well covered by operating cash flow (28.8%, greater than 20% of total debt).

Getinge is making a loss, therefore interest payments are not well covered by earnings.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.3x debt.


Next Steps

Dividend

What is Getinge's current dividend yield, its reliability and sustainability?

1.58%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Getinge's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Getinge's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

Getinge is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Getinge is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Getinge's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (3.2x coverage).


Next Steps

Management

What is the CEO of Getinge's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Mattias Perjos (47yo)

2.5yrs

Tenure

kr33,560,000

Compensation

Mr. Mattias Perjos has been the Chief Executive Officer and President at Getinge AB since March 27, 2017. Mr. Perjos serves as Chief Executive Officer at FlexLink Systems, Inc. Mr. Perjos has been the Dire ...


CEO Compensation Analysis

Mattias's remuneration is lower than average for companies of similar size in United States of America.

Mattias's compensation has increased whilst company is loss making.


Management Age and Tenure

2.5yrs

Average Tenure

52yo

Average Age

The tenure for the Getinge management team is about average.


Board Age and Tenure

5.7yrs

Average Tenure

59yo

Average Age

The tenure for the Getinge board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Mattias Perjos (47yo)

    CEO, President & Director

    • Tenure: 2.5yrs
    • Compensation: kr33.56m
  • Magnus Lundbäck (50yo)

    Executive Vice President of Human Resources & Sustainability

    • Tenure: 2.7yrs
  • Dieter Engel

    Chief Technology Officer of Surgical Workflows

    • Tenure: 3.7yrs
  • Lena Hagman (54yo)

    Executive Vice President of Quality & Regulatory Compliance

    • Tenure: 3.7yrs
  • Jens Viebke (52yo)

    President of Acute Care Therapies

    • Tenure: 0yrs
  • Lars Sandström (47yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
  • Carsten Blecker (53yo)

    Chief Commercial Officer

    • Tenure: 1.8yrs
  • Abraham Ronai

    General Counsel

    • Tenure: 0yrs
  • Lars Mattson

    Head of Investor Relations

    • Tenure: 0yrs
  • Jeanette Carlsson (53yo)

    Executive Vice President of Communications & Academy

    • Tenure: 2.3yrs

Board Members

  • Johan Bygge (63yo)

    Director

    • Tenure: 12.4yrs
    • Compensation: kr852.00k
  • Carl Bennet (68yo)

    Director

    • Tenure: 30.7yrs
    • Compensation: kr1.31m
  • Malin Persson (51yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: kr684.00k
  • Johan Stern (68yo)

    Vice Chairman

    • Tenure: 0yrs
    • Compensation: kr684.00k
  • Johan Malmquist (58yo)

    Chairman

    • Tenure: 0.4yrs
    • Compensation: kr684.00k
  • Cecilia Wennborg (56yo)

    Director

    • Tenure: 9.4yrs
    • Compensation: kr722.00k
  • Mattias Perjos (47yo)

    CEO, President & Director

    • Tenure: 2.5yrs
    • Compensation: kr33.56m
  • Barbro Fridén (63yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: kr684.00k
  • Peter Jörmalm (60yo)

    Employee Representative Director

    • Tenure: 1.7yrs
  • Rickard Karlsson (49yo)

    Employee Representative Director

    • Tenure: 6.7yrs

Company Information

Getinge AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Getinge AB
  • Ticker: GNGB.Y
  • Exchange: OTCPK
  • Founded: 1904
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr38.826b
  • Listing Market Cap: kr3.994b
  • Shares outstanding: 272.37m
  • Website: https://www.getinge.com

Number of Employees


Location

  • Getinge AB
  • Lindholmspiren 7
  • Gothenburg
  • Västra Götaland County
  • 417 56
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNGB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMay 1993
GETI BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKMay 1993
GTNDB (Deutsche Boerse AG)YesClass B SharesDEEURMay 1993
0GZVLSE (London Stock Exchange)YesClass B SharesGBSEKMay 1993
GETIBSBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKMay 1993
GNGB.YOTCPK (Pink Sheets LLC)UNSPONSORD ADRUSUSDOct 2008

Biography

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:57
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.